Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Azetukalner · XEN-1101

Small molecule · developed by Xenon Pharmaceuticals

Phase 3 Most advanced trial
XENE Developer
4 Registered trials

What is Azetukalner?

Azetukalner (XEN1101) is an orally administered agent given as a 20 mg capsule once daily in clinical studies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XEN-1101, 14C-XEN1101
Drug type
Small molecule
Therapy area
Neurology, Psychiatry
Developer
Xenon Pharmaceuticals Inc. (XENE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
91WL7OD122

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07217860 Phase 3 Bipolar Depression Active not recruiting XENE
NCT05667142 Phase 3 Primary Generalized Tonic-Clonic Seizures Recruiting XENE
NCT05376150 Phase 2 Major Depressive Disorder Completed XENE
NCT04952467 Phase 1 Healthy Volunteers Completed XENE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bipolar DepressionBipolar DisorderBipolar I DisorderBipolar II DisorderPrimary Generalized Tonic-Clonic SeizuresHealthy VolunteersMajor Depressive Disorder

More from Xenon Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the XENE page.

Follow XENE, the company behind Azetukalner

See XENE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XENE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.